ETNB News and Press, 89bio Inc. From 01/29/21

BIO89-100 is lead and only molecule targeting NASH with superior early-stage data. Among its peer group, molecule is well differentiated. Cash position is decent but not adequate to reach the market. For further details see: 89bio: NASH Drug Developer With Differentiated...

Our Roundtable series continues with a focus on biotech and healthcare investing. Apart from COVID-19 and vaccines, opportunities abound. The series will end this week with growth/tech investing and macro and technical analysis. For further details see: 2021 Roundtable: ...

89bio (ETNB) provided a corporate update, including its roadmap for advancing BIO89-100 in 2021.The Company is steadily executing across all clinical development program for BIO89-100, a potentially best-in-class FGF21 analog engineered to achieve superior efficacy, optimal dosing convenience...

-Phase 2b NASH trial as part of a potential Phase 2b/3 program expected to initiate in 1H21- -Topline data from recently initiated NASH paired-biopsy, open-label histology cohort expected by YE21- -Topline data from BIO89-100’s Phase 2 SHTG trial expected in 2H21-...

SAN FRANCISCO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the ...

SAN FRANCISCO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc . (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Pal...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadInvestors are likely to continue to hedge their bets between growth vs. value and vaccine plays vs. COVID shutdowns in th...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

– Data demonstrated compelling efficacy profile and favorable tolerability with weekly and every two-week dosing – – C onsistent results and baseline characteristics across biopsy confirmed and phenotypic NASH patients – ...